arrow
F

Francesca Gay

azienda ospedaliero-universitaria città della salute e della scienza di torino and university of torino
H指数:60
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus

优化三药类暴露复发/难治性多发性骨髓瘤患者中BCMA靶向T细胞结合疗法的实际应用:一项意大利改良德尔菲共识

Cancers
IF4.4
2026-08-110
OA
Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients

EMN12/HOVON-129研究移植适宜队列中初发浆细胞白血病患者长期随访

2026-06-240
OAAI
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma

移植适应证且先前未治疗的复发性骨髓瘤患者中,DVRd联合DR维持疗法(PERSEUS研究)与DVTd或VTd联合或不联合来那度胺维持疗法的间接治疗比较

2026-05-230
OAAI
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma

MDM2驱动蛋白酶体抑制剂耐药性,并在多发性骨髓瘤中代表一种TP53非依赖性的治疗易损性

Cells
IF5.2
2026-05-010
OA
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Isatuximab、carfilzomib、lenalidomide和dexamethasone在新诊断多发性骨髓瘤中的疗效:一项随机III期临床试验

2026-04-060
OAAI
Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
2026-01-080
OAAI
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

BCMA-和GPRC5D靶向免疫疗法在多发性骨髓瘤中的序贯治疗:欧洲骨髓瘤网络实用指南

2025-11-250
OAAI
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework

支持意大利多发性骨髓瘤患者在DRd治疗后进行治疗的决策制定:一个多准则决策框架

2025-11-020
OAAI
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data

基于注册数据的硼替佐米、来那度胺和地塞米松与预资助标准护理对新诊断多发性骨髓瘤的上市后经济评估

2025-10-290
PRE
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy

与骨髓瘤患者急性肾衰竭伴铸型肾病相关的肾恢复和生存参数

2025-10-240
OAAI
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma

欧洲骨髓瘤网络工作组关于下一代测序在 newly diagnosed multiple myeloma 预后分层中应用的共识声明

2025-10-130
OAAI
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients

来那度胺维持治疗在硼替佐米、沙利度胺和地塞米松(VTD)诱导治疗及自体干细胞移植后的应用:一项意大利真实世界研究,共纳入602例患者

2025-10-011
OAAI
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network

多发性骨髓瘤患者静脉血栓栓塞症的预防与治疗:欧洲骨髓瘤网络临床实践指南

2025-08-260
OAAI
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168

更正:Mancuso等人,《Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma》,《Cancers》2025年第17卷第1168页。

2025-08-200
PRE
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events

Belantamab Mafodotin相关眼部事件的临床管理实用指南

2025-07-280
OAAI
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions

Isatuximab在多发性骨髓瘤治疗中的应用:当前临床进展与未来方向

2025-07-230
OA